Saint Jean Groupe Société anonyme (EPA:SABE)
France · Delayed Price · Currency is EUR 19.10
0.00 (0.00%)
Aug 4, 2025, 5:24 PM CET
Ligand Pharmaceuticals Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 116.46 | 116.82 | 115.64 | 104.51 | 95.07 | 89.28 | Upgrade | |
Revenue Growth (YoY) | 0.51% | 1.02% | 10.65% | 9.92% | 6.49% | 9.51% | Upgrade |
Cost of Revenue | 53.47 | 52.82 | 52.89 | 50.52 | 43.55 | 39.8 | Upgrade |
Gross Profit | 62.99 | 63.99 | 62.74 | 53.99 | 51.52 | 49.47 | Upgrade |
Selling, General & Admin | 53.01 | 51.36 | 48.73 | 46.06 | 41.52 | 39.68 | Upgrade |
Other Operating Expenses | 0.47 | 0.28 | 0.87 | 1.32 | 1.22 | 1.74 | Upgrade |
Operating Expenses | 65.42 | 62.58 | 57.86 | 53.39 | 49.36 | 48.05 | Upgrade |
Operating Income | -2.43 | 1.42 | 4.88 | 0.6 | 2.17 | 1.42 | Upgrade |
Interest Expense | -0.78 | -0.79 | -0.68 | -0.29 | -0.33 | -0.45 | Upgrade |
Interest & Investment Income | 1.29 | 1.44 | 1 | 0.21 | 0.11 | 0.31 | Upgrade |
Other Non Operating Income (Expenses) | -0.03 | 0 | 0 | - | - | 0 | Upgrade |
EBT Excluding Unusual Items | -1.95 | 2.07 | 5.2 | 0.52 | 1.94 | 1.28 | Upgrade |
Gain (Loss) on Sale of Assets | -0.04 | -0.04 | 0.03 | 0.02 | 0.29 | 0.07 | Upgrade |
Pretax Income | -1.99 | 2.03 | 5.23 | 0.55 | 2.23 | 1.35 | Upgrade |
Income Tax Expense | -0.96 | 0.02 | 1.05 | -0.05 | 0.33 | 0.11 | Upgrade |
Earnings From Continuing Operations | -1.03 | 2.01 | 4.18 | 0.6 | 1.9 | 1.24 | Upgrade |
Net Income | -1.03 | 2.01 | 4.18 | 0.6 | 1.9 | 1.24 | Upgrade |
Net Income to Common | -1.03 | 2.01 | 4.18 | 0.6 | 1.9 | 1.24 | Upgrade |
Net Income Growth | - | -51.83% | 599.66% | -68.64% | 53.18% | -67.86% | Upgrade |
Shares Outstanding (Basic) | 3 | 3 | 3 | 3 | 3 | 3 | Upgrade |
Shares Outstanding (Diluted) | 3 | 3 | 3 | 3 | 3 | 3 | Upgrade |
Shares Change (YoY) | 2.12% | -0.18% | -4.47% | - | - | - | Upgrade |
EPS (Basic) | -0.32 | 0.63 | 1.30 | 0.18 | 0.57 | 0.37 | Upgrade |
EPS (Diluted) | -0.32 | 0.63 | 1.30 | 0.18 | 0.57 | 0.37 | Upgrade |
EPS Growth | - | -51.74% | 632.38% | -68.62% | 53.24% | -67.88% | Upgrade |
Free Cash Flow | -3.23 | -2.89 | -6.58 | -12.55 | -14.81 | -5.15 | Upgrade |
Free Cash Flow Per Share | -1.01 | -0.90 | -2.05 | -3.74 | -4.41 | -1.53 | Upgrade |
Dividend Per Share | - | - | 0.100 | 0.100 | 0.100 | - | Upgrade |
Gross Margin | 54.09% | 54.78% | 54.26% | 51.66% | 54.20% | 55.42% | Upgrade |
Operating Margin | -2.08% | 1.21% | 4.22% | 0.57% | 2.28% | 1.59% | Upgrade |
Profit Margin | -0.88% | 1.72% | 3.61% | 0.57% | 2.00% | 1.39% | Upgrade |
Free Cash Flow Margin | -2.77% | -2.47% | -5.69% | -12.01% | -15.57% | -5.76% | Upgrade |
EBITDA | 8.76 | 11.54 | 13.14 | 6.61 | 8.95 | 8.06 | Upgrade |
EBITDA Margin | 7.52% | 9.88% | 11.36% | 6.32% | 9.41% | 9.03% | Upgrade |
D&A For EBITDA | 11.19 | 10.12 | 8.26 | 6.01 | 6.78 | 6.64 | Upgrade |
EBIT | -2.43 | 1.42 | 4.88 | 0.6 | 2.17 | 1.42 | Upgrade |
EBIT Margin | -2.08% | 1.21% | 4.22% | 0.57% | 2.28% | 1.59% | Upgrade |
Effective Tax Rate | - | 0.84% | 20.07% | - | 14.70% | 7.93% | Upgrade |
Updated Aug 1, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.